You are here

AstraZeneca

Drug companies pay for exclusive access to UK genetic data

Biopharma Dive

Thu, 09/12/19 - 11:35 am

genetic database

At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

Xconomy

Mon, 09/9/19 - 08:08 pm

Blueprint Medicines

PhIII lung cancer data signals potential approval for AstraZeneca's Imfinzi

Endpoints

Mon, 09/9/19 - 10:24 am

clinical trials

Small-Cell Lung Cancer

AstraZeneca aims to pump up Farxiga marketing after cardio outcomes study

Fierce Pharma

Fri, 09/6/19 - 12:38 pm

ESMO 2019 preview – PARPs on parade

EP Vantage

Thu, 09/5/19 - 12:06 pm

PARP inhibitors

More to come from PARP drugs, says biotech CEO after striking radiotherapy deal with AZ

Pharmaforum

Thu, 09/5/19 - 10:15 am

PARP inhibitors

ESC: AstraZeneca's SGLT2 med Farxiga flips script on competitors with 26% CV risk cut

Fierce Pharma

Wed, 09/4/19 - 11:48 am

AZ gets China nod for Tagrisso in first-line lung cancer

Pharmaforum

Wed, 09/4/19 - 11:22 am

non-small cell lung cancer

Heart failure results could unlock key market for Farxiga – AZ

Pharmaforum

Mon, 09/2/19 - 12:22 pm

One year after flop, AstraZeneca's phase 3 lupus trial hits endpoint

Fierce Biotech

Thu, 08/29/19 - 10:30 am

clinical trials

systemic lupus erythematosus

AstraZeneca’s Fasenra gets FDA ODD status for eosinophilic oesophagitis

Pharmaceutical Business Review

Thu, 08/29/19 - 10:28 am

eosinophilic esophagitis

AstraZeneca respiratory business gets boost from 3-drug inhaler results

Yahoo/Reuters

Wed, 08/28/19 - 10:52 am

U.S. FDA gives fast track status to AstraZeneca's diabetes drug Farxiga

Yahoo/Reuters

Tue, 08/27/19 - 09:31 am

chronic kidney disease

AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China

Yahoo/Zacks.com

Fri, 08/23/19 - 10:04 am

chronic kidney disease

AstraZeneca pays Sobi $95M for priority review voucher

Fierce Biotech

Thu, 08/22/19 - 11:57 am

priority review vouchers

AstraZeneca Imfinzi combination fails advanced lung cancer study

Yahoo/Reuters

Wed, 08/21/19 - 09:31 am

advanced non-small cell lung cancer

AstraZeneca's diabetes drug Farxiga helps patients with heart disease and without diabetes in landmark trial

Endpoints

Tue, 08/20/19 - 10:28 am

cardiovascular disease

AstraZeneca drug heads to phase 2 in pancreatic cancer after small trial extends survival

Fierce Biotech

Thu, 08/15/19 - 12:27 pm

pancreatic cancer

University of Michigan

Which pharmas grew most in Q2? AstraZeneca, Merck and BMS, for 3

Fierce Pharma

Thu, 08/15/19 - 10:42 am

Bristol-Myers Squibb

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment

Pharmaforum

Wed, 08/14/19 - 11:01 am

clinical trials

advanced ovarian cancer

Pages